Katarzyna Derwich Selected Research

New York protocol

1/2010

[Long-term observations of children with acute lymphoblastic leukemia and high leukocytosis treated according to modified "New York" protocols (1987-2003)].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Katarzyna Derwich Research Topics

Disease

14	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021 - 01/2006
7	Leukemia 01/2022 - 05/2009
7	Residual Neoplasm 01/2021 - 01/2006
5	Neoplasms (Cancer) 01/2022 - 01/2008
2	Neuroblastoma 01/2021 - 01/2008
2	Lymphoma (Lymphomas) 12/2020 - 01/2010
2	Cognitive Dysfunction 01/2020 - 02/2017
1	Cytokine Release Syndrome 01/2022
1	Wounds and Injuries (Trauma) 01/2021
1	Aneuploidy (Aneuploid) 01/2021
1	Philadelphia Chromosome 12/2020
1	Aplastic Anemia (Anemia, Hypoplastic) 10/2020
1	Body Weight (Weight, Body) 06/2019
1	Transfusion Reaction 06/2019
1	Pancreatitis 01/2019
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 08/2017
1	Down Syndrome (Down's Syndrome) 05/2017
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 06/2015
1	Myeloid Sarcoma (Chloroma) 06/2015
1	Leukocytosis (Pleocytosis) 01/2010
1	Acute Biphenotypic Leukemia (Leukemia, Mixed Cell) 07/2009
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 05/2009
1	Infertility (Sterility) 10/2008
1	Neoplasm Metastasis (Metastasis) 01/2008
1	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2006
1	Second Primary Neoplasms (Neoplasms, Second) 01/2006

Drug/Important Bio-Agent (IBA)

4	Immunoglobulins (Immunoglobulin)IBA 06/2019 - 01/2006
3	Methotrexate (Mexate)FDA LinkGeneric 10/2018 - 01/2006
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 11/2008 - 01/2006
2	Pharmaceutical PreparationsIBA 01/2022 - 01/2019
2	Biological ProductsIBA 01/2021 - 01/2019
2	AntigensIBA 01/2021 - 07/2009
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2006
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	Chimeric Antigen ReceptorsIBA 01/2022
1	CytokinesIBA 01/2022
1	Tyrosine Kinase InhibitorsIBA 12/2020
1	Intravenous Immunoglobulins (IVIG)FDA Link 06/2019
1	SteroidsIBA 01/2019
1	Asparaginase (Elspar)FDA Link 01/2019
1	Cytokine Receptors (Cytokine Receptor)IBA 05/2018
1	Chromogranin AIBA 08/2017
1	Interleukin-15 (Interleukin 15)IBA 01/2016
1	Imatinib Mesylate (Gleevec)FDA Link 06/2015
1	AntibodiesIBA 01/2013
1	Clofarabine (Clolar)FDA Link 05/2009
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2008
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2008
1	Vascular Endothelial Growth Factor CIBA 01/2008

Therapy/Procedure

10	Therapeutics 01/2022 - 01/2006
5	Drug Therapy (Chemotherapy) 12/2020 - 10/2008
3	Radiotherapy 10/2018 - 10/2008
2	Aftercare (After-Treatment) 06/2015 - 10/2008
1	Operative Surgical Procedures 01/2021
1	Induction Chemotherapy 01/2021
1	Hematopoietic Stem Cell Transplantation 01/2020
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 06/2015
1	New York protocol 01/2010